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Retinoblastoma Management: 
Advances in Chemotherapy
Amani Al Kofide and Eman Al-Sharif
Abstract
The treatment of children with retinoblastoma (RB) has evolved from primarily 
enucleation of the eye(s) to highly selective methods of chemotherapy administra-
tion and approach. Indulgent and comprehensive understanding of the multitude 
of factors including accurate classification and grading of disease, timing and 
response to therapy, when to consolidate with local methods of therapy, combina-
tion regimens to control systemic disease and prevent relapse while minimizing 
risk of secondary cancers are crucial factors in the management of children with 
retinoblastoma. Chemotherapy was introduced in the 1950s and has become an 
integral component in management of RB. Methods of administration range from 
systemic to locally directed therapy including; intravitreal, periocular and intra-
arterial chemotherapy. This chapter is intended to discuss the evolution and current 
chemotherapeutic agents with various routes of administration. The indications, 
adverse occurrences, short- and long-term complications of both local and systemic 
treatments will be elucidated.
Keywords: chemotherapy, retinoblastoma, metastasis, intravenous, intra-arterial, 
intravitreal, periocular, vitreous seeds
1. Introduction
The treatment of retinoblastoma is challenging, as the governing objectives are 
preserving life, protecting from pineoblastoma, decreasing the lifetime incidence of 
secondary tumors and salvaging useful vision without exposing the patient to sig-
nificant and serious side effects that may endanger the patient’s survival and quality 
of life. The treatment of retinoblastoma evolved steadily during the past decades, 
and multiple modalities of treatment were introduced including chemotherapy. At 
one time, chemotherapy was used mainly to manage metastatic retinoblastoma, 
but later the interest of scientists and clinicians shifted to the use of this treatment 
strategy for non-metastatic retinoblastoma. As the interest of experts grew and 
the demand for better overall outcome increased, multiple interesting treatment 
strategies were developed and refined. Now, four main routes of administration of 
chemotherapy are present, and these are: intravenous chemotherapy (IVC), intra-
arterial chemotherapy (IAC), intravitreal chemotherapy (IVitC) and periocular 
chemotherapy (POC).
Today, chemotherapy is regarded as one of the indispensable pillars of treatment 
of retinoblastoma. In fact, retinoblastoma is currently one of the most commonly 
curable childhood malignant tumors universally. In developed countries, the rates 
of expected survival exceed 95% whereas the rates in developing countries are 
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lower due to the limited healthcare resources [1]. The different chemotherapy 
treatment strategies outlined above will be discussed thoroughly in the upcoming 
sections.
2. Intravenous chemotherapy for retinoblastoma
The era of chemotherapeutic treatment for retinoblastoma began in 1953 when 
Carl Kupfer reported the successful use of intravenous nitrogen mustard along with 
irradiation to treat a child with recurrent retinoblastoma [2]. Thereafter, the use 
of triethylene melamine, a chemotherapeutic alkylating agent, via different routes 
(oral, intramuscular, intravenous and intra-arterial) became more widespread 
between clinicians until the late 1960s given that it allowed the reduction of radio-
therapy dose which was associated with multiple potential side effects [3–6]. In the 
following years, the use of systemic chemotherapy fluctuated until the early 1990s 
when the use of systemic chemotherapy was popularized and strongly advocated 
by the leading retinoblastoma treatment centers worldwide and the use of external 
beam radiation was restricted in favor of chemotherapy due to the considerable risk 
of secondary tumors in patients receiving radiotherapy.
The management of retinoblastoma should be carried out by an experienced 
team as these children need meticulous bilateral ocular examination, usually 
under anesthesia, in parallel with systemic evaluation by a pediatric oncologist 
with experience in ocular oncology and appropriate systemic imaging by magnetic 
resonance imaging (MRI) must be standardly performed to rule out metastasis. 
These steps are vital to accurately classify the disease in accordance with the more 
recent International Classification of Retinoblastoma (ICRB). This will direct the 
treatment to either systemic chemotherapy or local therapies (thermal, cryotherapy 
and chemotherapy) or a combination of both.
Understating the effect of systemic chemotherapy on the different forms of 
retinoblastoma (solid tumor, subretinal tumor and vitreous seeds) is essential as 
it helps in guiding the treatment. Moreover, the likely complications and systemic 
toxicities of IVC are important to be looked at carefully before commencement as 
this will help in individualizing the treatment in this vulnerable subset of patients 
so as to reduce systemic morbidities without jeopardizing the treatment success 
[7]. In this section, we will highlight the principal characteristics of this treatment 
modality.
2.1 Indications
The use of IVC varies slightly between different treatment centers worldwide; 
but generally speaking, the umbrella of IVC usage encompasses its use in patients 
with intraocular disease only and in patients with or at high risk of extraocular 
disease. When the disease is limited to the eyes, IVC aims at shrinking the size of 
the tumor to expedite cure and lessen the damage induced by consolidating local 
therapies to follow, especially when the tumor involves sensitive retinal areas such 
as the macula. This has been termed chemoreduction and it had been shown to 
achieve adequate tumor control (alone or along with focal consolidating therapies) 
and eliminate the need for enucleation or external beam radiation (EBR) in more 
than 75% of patients in a large series (n = 457, group A–D). The risk of recurrence 
in this series was 22% and these were usually detected in the first year after starting 
the treatment; yet; none occurred by 4 years of follow up [8, 9]. This is probably the 
most important concern arising with the use of chemoreduction; though continu-
ous surveillance of these children partly helps in overcoming this shortcoming. 
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Moreover, one study suggested that the administration of chemoreduction might 
minimize the risk of pineoblastoma where none of the children (n = 147) receiving 
this therapy developed trilateral retinoblastoma [10].
IVC is used also as an adjuvant therapy after enucleation in patients with 
extraocular disease (metastasis) as well as patients with intraocular disease associ-
ated with high-risk histopathological features (e.g., optic nerve invasion beyond the 
lamina cribrosa and choroid invasion >3 mm) demonstrated on histopathological 
examination of the enucleated eye [11]. It is speculated that patients with high-risk 
features might presumably have micro-metastasis and administering systemic 
chemoprophylaxis helps in improving their prognosis. Evidence in the literature 
supports the use of prophylactic IVC in high-risk patients where it was shown that it 
is safe and effective in decreasing the risk of metastasis [12, 13].
Patients with extraocular disease receiving IVC can be divided into three 
categories: those with orbital and/or regional spread to the preauricular lymph 
nodes or optic nerve cut, those with central nervous system (CNS) dissemina-
tion and those with distant extracranial metastasis [14]. In patients presenting 
with orbital retinoblastoma, IVC is a valuable treatment. This holds true when it 
is predominantly administered in combination with other therapies (multimodal 
therapy: surgery, radiotherapy and chemotherapy) as its effect is usually inad-
equate when given alone [15]. Patients who have CNS involvement usually have a 
very poor prognosis with low survival rate. The usual approach to these patients 
consists of platinum-based IVC with agents having good CNS penetration along 
with focal CNS treatments such as radiotherapy. Some studies suggested using high 
doses of IVC followed by autologous hematopoietic progenitor cell rescue; yet, this 
technique is controversial [16]. Distant metastasis usually occurs to the bone and a 
small series (n = 14) on stage 4A patients showed promising results using intense 
induction chemotherapy followed by high dose consolidating chemotherapy and 
autologous hematopoietic progenitor cell rescue [17].
2.2 Chemotherapeutic protocol
Over the past decades, multiple chemotherapeutic agents were used, and 
multiple chemotherapy protocols were implemented, some of which are now 
outdated. In the meantime, the most commonly employed IVC therapy is the VEC 
protocol consisting of three main chemotherapeutic agents (Vincristine, Etoposide, 
Carboplatin) in standard doses based on the body weight. Higher doses may be used 
in patients with more advanced disease (bilateral group D or E) [7, 18]. This three-
drug regimen is the most popular combination preferred by many experts and this 
stems from its proven effect on neuronal tumors in the pediatric age group as well 
as its good penetration into the eye [19]. The patient usually receives 6–9 cycles on a 
monthly basis and once the tumor shrinks in size, then focal consolidating treat-
ments can follow [7].
2.3 Complications
Common side effects, which are usually observed with any systemic chemo-
therapy, include transient pancytopenia owing to bone marrow suppression, fever 
and alopecia. The occurrence of these side effects is usually limited to the treatment 
period. Although carboplatin, a platinum based agent, had been linked to ototoxic-
ity and nephrotoxicity, these serious side effects are rare as they are dose-dependent 
[20, 21]. There was an underlying concern that etoposide may induce acute myelog-
enous leukemia especially with high multiple doses; yet, the results of several 
studies on this topic were reassuring [7, 22]. With regards to secondary tumors, it 
Retinoblastoma - Past, Present and Future
4
does not seem that IVC increases the risk ominously. A long term follow-up study 
demonstrated that the rate of secondary tumors in germline retinoblastoma patients 
treated with systemic chemotherapy was 4%, which is less than expected for this 
vulnerable subset of patients [23].
2.4 Outcomes and success rate
The introduction of systemic chemotherapy resulted in an improved eye salvage 
rate, not to mention the enhanced visual outcome. Chemoreduction success can 
be predicted in patients with retinoblastoma following the ICRB classification as 
following: 100% in group A, 93% in group B, 90% in group C and <50% in group D 
and E [24]. The success rate in the advanced stages can be augmented when combin-
ing IVC with other modalities of treatment such as IAC or IVitC. Long-term studies 
have shown that chemotherapy with or without adjunctive therapies maintains 
ambulatory vision of ≥6/60 in almost two-thirds of the patients, particularly those 
with multiple tumors and/or no foveolar tumors [25]. Furthermore, IVC seems to 
exert a protective effect against pineoblastoma as its occurrence is usually very low 
in patients receiving it [26].
The effect of systemic chemotherapy as a monotherapy appears to be satisfac-
tory especially in patients with less advanced disease whereas in patients with 
advanced disease, its remedial action is complementary to the selective recent 
therapies. A recently published meta-analysis comparing IVC to the more selective 
IAC revealed that both methods are equivalent in terms of tumor recurrence and 
metastasis. IAC evidently had a higher total success rate and ocular sparing effect 
in group D patients compared to IVC [27]. Despite this, we believe that IVC will 
continue to be an integral part of the treatment regimen of retinoblastoma.
3. Intra-arterial chemotherapy for retinoblastoma
Intra-arterial chemotherapy (IAC), also known as ophthalmic artery chemo-
surgery (OAC), is an important treatment strategy for retinoblastoma that evolved 
rapidly and gained popularity worldwide. Today, this modality of treatment is being 
performed in many retinoblastoma treatment centers located in more than 45 coun-
tries across the globe [28]. This treatment modality was initially explored by Reese 
et al. [3] who directly injected the alkylating agent triethylene melamine (TEM) 
into the internal carotid artery; nevertheless, it was not until 2006 when Abramson 
and Gobin introduced the novel technique of super-selective ophthalmic artery 
catheterization via transfemoral artery approach which allowed immediate and 
effectual delivery of the administered agent (melphalan) into the diseased eye [29]. 
Thereafter, many oncology centers adopted this technique and started publishing 
their experience. In this section, we will be shedding the light on the important 
aspects and most recent results of IAC.
3.1 Indications
IAC opened the door to a new era in the treatment of retinoblastoma. The key 
exciting factor behind this local therapy is its ability to achieve adequate therapeutic 
intraocular concentrations of the delivered chemotherapeutic agents while minimiz-
ing the systemic toxicity induced by these infused drugs such as neutropenia and 
secondary tumors [30]. In view of this, IAC is utilized mainly in treating patients 
with intraocular disease without local or systemic spread. Previous studies on IAC 
have shown that it can be used successfully as a primary retinoblastoma treatment in 
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naïve eyes (no previous therapy employed) or as a secondary treatment in eyes with 
recurrent or residual tumor after trying other treatment modalities such as systemic 
chemotherapy, external beam radiotherapy and others [29, 31–37]. Currently, the 
common indications for IAC in retinoblastoma patients include unilateral retino-
blastoma that cannot be halted by local treatments alone (e.g., cryotherapy or laser 
photocoagulation) and advanced unilateral retinoblastoma (such as group D and 
E based on the ICRB) [30]. Several studies had previously reported the following 
advantages of using IAC in patients with group D retinoblastoma: better eye conser-
vation rates and greater visual acuity compared to systemic chemotherapy, shorter 
treatment period and ability to repeat the therapy several times using multiple agents 
without endangering the patients’ life and vision [28, 38]. It is also noteworthy to 
mention that IAC can save naïve eyes with advanced retinoblastoma from enucle-
ation particularly when subretinal seeding is present (2 year ocular survival rate of 
83%) [39]. Furthermore, IAC has a proven benefit even in patients presenting with 
advanced disease such as those having retinoblastoma-induced total or partial retinal 
detachment in which it can successfully achieve retinal re-attachment and thus help 
in preserving the eye and the life with the least possible side effects [40, 41].
Simultaneous IAC (tandem therapy) to both eyes consecutively is also a valu-
able and safe treatment method in patients with bilateral germline retinoblastoma 
whether used primarily or secondarily. This was demonstrated in two recent stud-
ies, which reported excellent globe salvage rates (ocular survival rate > 90%) even 
in patients with advanced disease. Despite that the safety profile of this simultane-
ous therapy was considerably high where no treatment-associated deaths occurred, 
these children were still at risk of secondary tumors such as pineoblastoma and this 
is probably attributed to their inherent genetic predisposition [42, 43].
3.2 IAC technique
The technique of IAC is carried out on patients who are generally anesthetized and 
is usually coordinated by a specialized and experienced oncology/radiology team. The 
common femoral artery on the ipsilateral treatment side is usually used to gain access 
to the internal carotid artery and then the ophthalmic artery (OA) is selectively cath-
eterized under fluoroscopic guidance at its ostium (origin) while heparin is infused 
intravenously to prevent coagulation. Then, in order to verify the proper placement 
of the microcatheter, selective angiography is done by contrast infusion to delineate 
the vascular anatomy and ocular perfusion. Due to the variability of vascular territory 
anatomy and blood flow patterns, OA catheterization might fail and other routes are 
available, however, this is out of the scope of this chapter [34].
3.3 Chemotherapeutic agents
The most commonly used intra-arterial chemotherapeutic agent is melphalan, 
a potent alkylating agent. Melphalan is by far the strongest chemotherapeutic 
drug acting effectually against human retinoblastoma cells [44]. It is very safe 
when administered locally but very toxic when infused systemically due to the 
resultant severe myelosuppression [45]. In fact, it is currently considered an ideal 
agent due to its favorable safety profile, short half-life and ability to be used in 
combination with other agents to achieve greater tumor control when needed 
[34, 46]. Topotecan, a topoisomerase inhibitor, and carboplatin, an alkylating 
agent, are other agents that have been used alone or as a part of a multi-drug 
regimen in advanced cases that fail to respond to melphalan solitarily or in 
bilateral tandem therapy where the dose of melphalan is decreased to prevent 
systemic side effects [34].
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3.4 Complications
Despite being a less invasive therapeutic intervention, IAC does carry some 
risk of complications, as it would be expected with any medical interventional 
procedure. Complications occurring after IAC are attributed either to the procedure 
itself or to the chemotherapeutic agent/agents or both. Complications developing 
from the procedure include endovascular complications occurring intraoperative, 
allergy to iodine and hematoma at the site of entry into the femoral artery. Systemic 
thromboembolic and hemorrhagic events (stroke, limb ischemia) are possible but 
their current reported overall occurrence is extremely scarce [30, 44]. Up to date, 
no procedure-related deaths had been reported. Theoretically speaking, since IAC 
targets chiefly the intraocular pathology, the risk of metastasis and secondary 
neoplasms remains unchanged or even might be increased, as this treatment is not 
intended to reach the systemic circulation in high concentrations. Experts studied 
the incidence of death due to retinoblastoma-associated metastasis in a cohort of 
patients treated over a 10-year period by IAC primarily or secondarily and found it 
to be negligible (<1%) [47]. Likewise, IAC was not associated with an increased rate 
of second primary malignancies (SPM) in a group of patients with germline reti-
noblastoma from one treatment center studied over a 10-year period (2006–2016) 
[48]. However, IAC is relatively a recent therapy; therefore, it is still premature 
to derive definite conclusions regarding the potential risk and studies with longer 
follow up periods are required.
Neutropenia is another important complication that should be recognized and 
managed early to prevent devastating complications. The local distribution of the 
drug has helped in limiting its occurrence to <15% [34, 49]. On the other hand, 
minor ocular side effects are common and these include: lids edema, blepharoptosis, 
temporary loss of the eyelashes and forehead hyperemia along the distribution of 
the supratrochlear artery [50]. Ocular vascular complications are among the univer-
sally feared local side effects. A recent review of 16 published studies reported that 
<2.5% had ophthalmic artery obstruction or occlusion, choroidal ischemia or atro-
phy and vasospasm [49]. These vascular events should be interpreted in the context 
of the clinical case given that these are usually sick eyes that might have received 
other local treatments that might contribute to the occurrence of such events. A 
recently published study looked at the incidence of vascular events and the variabil-
ity of their occurrence when IAC is given primarily or secondarily and reported the 
following: overall vascular complications occur in 5% of eyes per infusion and no 
difference was observed when IAC is used as a primary or secondary therapy [51].
3.5 Outcomes and success rate
The body of evidence in the literature supporting the use of IAC has been 
growing persistently in the past decade. Impressively, the reported globe salvage 
rate is currently exceeding 90% without compromising patient’s survival and the 
enucleation rate dropped to <10% [35, 52–54]. Even the rate of orbital recurrence 
was significantly higher in patients with advanced disease treated with enucleation 
compared to IAC and this further emphasizes the gainful outcome of IAC [55].
A major concern about the risk of recurrence after IAC treatment remains in 
spite of the success achieved by this treatment modality. A recent study from one of 
the pioneering centers utilizing IAC with 10 years experience reported that around 
25% of eyes treated primarily with IAC might develop recurrence. The recurrence 
of the disease was observed to occur mainly in the first 12 months post-treatment; 
and therefore, close follow up with serial meticulous examination is recommended 
during this period. Surprisingly, the rate of recurrence was higher in eyes that 
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received the drug through routes other than OA and in eyes with widely spaced 
treatments more than 4 weeks. The risk of recurrence was <10% by 2 years in eyes 
remaining disease free in the first year after IAC [52].
4. Intravitreal chemotherapy for retinoblastoma
Intravitreal chemotherapy (IVitC) is another well-established targeted therapy 
accounting for one of the important current treatment modalities for retinoblas-
toma manifesting vitreous seeds. Initial reports on IVitC date back to the 1960s 
where thiotepa was injected into the vitreous cavity of six eyes with retinoblastoma; 
yet the results were inconclusive due to the limited number of treated eyes [56]. 
Later, this method was revived by Kaneko and Suzuki who injected melphalan 
intravitreally in 41 eyes along with ocular hyperthermia to cure vitreous seed-
ing with a notable resultant eye preservation rate of 51.3% [57]. The choice of 
melphalan was essentially based on in-vitro testing of 12 anti-neoplastic drugs, 
and melphalan proved to be the most effective against retinoblastoma cells [45]. 
Implementing this technique into current practice took several years and perhaps 
the major limiting factor was the fear of disseminating the cancer cells during injec-
tion with the risk of subsequent extraocular spread causing metastasis and death. 
This section will elaborate on the key qualities of this relatively new therapy.
4.1 Indications and contraindications for intravitreal chemotherapy
This local therapeutic technique is intended essentially to achieve the highest 
concentration of the delivered tumoricidal drug into the confined intraocular space 
adjacent to the tumor. IVitC is used as an adjunctive therapy to chemoreduction 
with systemic chemotherapy and IAC. The main indications for this treatment 
modality are the presence of active vitreous seeds that are either refractory to stan-
dard therapy or recurrent after pervious standard therapy [7]. The use of IVitC had 
also expanded lately to include patients with retinal and subretinal tumors where it 
had been shown to be successful in salvaging the globe of such patients [58].
On the other hands, contraindications preventing the execution of this pro-
cedure include tumors involving the ciliary body or extending up to the anterior 
segment, tumors filling the globe, retinal detachment and vitreous hemorrhage.
4.2 Intravitreal chemotherapy technique
Before proceeding with this treatment, it is critical to meticulously evaluate the 
pars plana clinically in all quadrants 360° looking for any tumor foci as that could 
pose a threat to safety if present due to the risk of spread while injecting. If visual-
ization is difficult, then ultrasound biomicroscopy can be used to help in detection 
and affirmation [59].
The procedure is usually carried out in the operating room under sterile condi-
tions while the child is under general anesthesia. The anti-cancerous drug, typically 
melphalan, is injected through the pars plana 3–3.5 mm from the limbus into the 
vitreous cavity using a small needle, preferably a 32 gauge-needle. This creates the 
smallest needle track that helps in reducing the risk of dissemination. The injection 
is rather done in a seed-free quadrant, 2 o’clock hours away from vitreous seeds to 
prevent the undesirable exteriorization of tumor cells. Furthermore, some experts 
advocate reducing the pressure inside the eye by paracentesis before inserting the 
needle to prevent the possible risk of microscopic tumor seeding. After injecting the 
drug and before exiting the tumor-harboring globe, triple freeze-thaw cryotherapy 
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should be carried out concurrently at the injection site while withdrawing the 
needle. Then, uniform intraocular distribution of the drug is achieved by gentle 
shaking of the eye using forceps. Examination is usually performed at the end of the 
procedure to rule out possible acute complications such as retinal detachment and 
bleeding. The ocular surface is then washed with balanced salt solution to remove 
any remnant chemotherapeutic agent that could be toxic. The child is usually dis-
charged in the same day and the family is instructed to avoid touching the eye [59]. 
The procedure may vary minimally between different specialized treatment centers.
4.3 Chemotherapeutic agents
Melphalan hydrochloride is the principal drug injected into the vitreous cav-
ity in retinoblastoma patients. It is a cytotoxic nitrogen mustard derivative that 
inhibits the synthesis of DNA and RNA together [59]. Its effective dosage range was 
studied and set at 20–30 μg per injection as low doses (8 μg) were not adequate to 
control and eradicate the disease while high doses (50 μg) controlled the disease 
but resulted in local toxicity (cataract, posterior segment hemorrhage, hypotony 
and phthisis bulbi) [60]. The number of injections is governed by the response. 
In general, Shields et al. proposed giving a total of six injections weekly or every 
2 weeks [7].
Topotecan, a topoisomerase-1 inhibitor, is another potent intravitreal agent 
that had been employed in the treatment of retinoblastoma with vitreous seeds. 
Experimental animal studies showed that topotecan produce high and stable levels 
in the vitreous [61]. One of the distinguishable advantages of topotecan is its ability 
to attain a vitreous-to-plasma concentration five times more than melphalan [62]. 
Previous studies have shown that it is an effective anti-tumor drug with good safety 
profile and low ocular toxicity [63]. It had been used intravitreally in combination 
with melphalan in humans with encouraging results where this multi-agent regimen 
managed to achieve notable vitreous seeds regression with fewer injections [64]. 
Topotecan can also be used effectively in patients with recurrent or resistant viable 
vitreous seeds according to a recent study on 17 eyes which demonstrated control 
of these seeds in all treated eyes (100%) in the absence of ocular or systemic side 
effects and with a lower number of injections [65].
4.4 Complications
Extraocular tumor dissemination through the needle track with subsequent 
metastasis was perhaps the most feared serious event limiting the use of this treat-
ment modality in the past. However, a meta-analysis examining published studies 
on this matter revealed that the risk of systemic spread is very low (two cases out 
of 1304 injections, proportion of extraocular spread secondary to injections was 
0.007) especially when the appropriate safety enhancing injection techniques 
are applied. Therefore, IVitC can be utilized unreservedly whenever needed after 
proper patient selection [66].
Ocular side effects are generally uncommon in patients receiving IVitC. The 
major factor influencing the risk of complications and local ocular toxicity is the 
dose of administered medication where toxicity is more likely with melphalan doses 
higher than 30 μg [67]. Among the most frequent side effects is retinal pigment 
epithelium changes (salt and pepper retinopathy), which is believed to represent a 
form of chemical burn to the retinal at the area where the drug is concentrated the 
most [68, 69]. Retinal function decline due to toxicity, usually highlighted on elec-
troretinography (ERG), is a possible complication of melphalan although the results 
are conflicting in the literature where one study showed no effect on ERG (dose: 
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20–30 μg) while another reported non-progressive decreased ERG amplitudes of 
approximately 5 μV (equivalent to 5% retinal response) with every 30 μg melphalan 
injection [70–72]. ERG can actually be a useful tool to monitor these patients for 
cumulative retinal toxicity.
Other major ocular complications that were highlighted in a systematic review 
with a total of 1287 intravitreal injections given to 306 eyes include: iris depigmen-
tation and atrophy, chorioretinal atrophy with vitreous hemorrhage and retinal 
detachment [67]. Fortunately, there are no reports of endophthalmitis after IVitC; 
nonetheless, all protective measures should be taken to prevent this possible devas-
tating complication.
With regards to serious systemic side effects, namely significant neutropenia 
of grade 3 and 4, these were not observed when analyzing 46 blood samples with-
drawn from patients receiving IVitC (despite some patients received concurrent 
IAC) [71]. Again, this accentuates the benefit of local therapies in these young 
children.
4.5 Outcomes and success rate
Treating retinoblastoma with vitreous seeding can be really challenging due to 
the avascular nature of the vitreous; and therefore, drug delivery through systemic 
routes may not be sufficient sometimes. Besides this, it tends to be resistant to 
external radiation and systemic chemotherapy [68, 73]. In the past two decades, a 
quantum leap forward in the management of advanced retinoblastoma was reached 
with the help of IVitC. The reported vitreous seeding control rates of IVitC (mel-
phalan with or without topotecan) ranges between 60 and 100% [60, 68, 71, 72, 
74]. Additionally, the attained globe salvage rates are also impressive reaching up to 
100% as reported in one study on 11 eyes receiving a total of 55 intravitreal melpha-
lan injections [69].
5. Periocular chemotherapy for retinoblastoma
Periocular chemotherapy (POC) administration was designed to allow deliv-
ery of a higher concentration of the tumoricidal drugs locally. This route was 
firstly tested in retinoblastoma animal models using carboplatin and it had been 
shown that this route produces vitreous concentrations 8–10 folds more than the 
intravenous route [75, 76]. These preclinical results led to the conduction of a trial 
in which children with retinoblastoma were treated using subconjunctival carbo-
platin and the results were promising [77]. Thereafter, POC grew in popularity 
and it was consequently incorporated into the multimodal treatment algorithm 
of retinoblastoma. Currently, it is a part of the prospective multicenter Children’s 
Oncology Group trials for retinoblastoma. In this section, POC will be tackled 
comprehensively.
5.1 Indications for periocular chemotherapy
POC is used predominantly as an adjunctive therapy to systemic chemotherapy 
as presently there is no evidence promoting it as a stand-alone therapy [78]. It is 
indicated principally in patients with recurrent localized tumor and in advanced 
disease (group D and E) where chemotherapy can be desirably infused in higher 
concentrations without exposing the patient to increased systemic toxicity [7]. It can 
also be utilized in patients who are not fit to receive systemic chemotherapy as well as 
patients with recurrent or persistent viable non-calcified vitreous seeds [78].
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5.2 Chemotherapeutic agents
The common chemotherapeutic agents that are mostly used are carboplatin and 
topotecan. Experimental work showed that carboplatin peaks in the vitreous after 
30 min of periocular injection and lasts for hours. Its concentration in the vitreous 
is approximately seven times more than that achieved by intravenous chemotherapy 
[76]. Several periocular drug administrative devices were explored and these 
include: plain liquid, Lincoff balloon, fibrin sealant, nanoparticles and iontophore-
sis [76, 79–81].
5.3 Complications
This treatment modality fortunately has no systemic side effects. Ocular 
complications do occur, and these mostly affect the periorbital tissue possibly 
owing to local toxicity. The most common observed side effects are lid edema, 
lid erythema, periorbital pseudocellulitis, ptosis, orbital fat atrophy, optic nerve 
atrophy and muscle fibrosis causing ocular motility changes [7, 77, 78, 82, 83]. 
Concerns were raised regarding the toxic effect on the extraocular muscles; yet, 
a study examining the effect of sub-tenon topotecan on the extraocular muscles 
of 10 eyes concluded that it had no toxic effect on the muscles and it is a safe and 
effective alternative [84].
5.4 Outcomes and success rate
Although the number of studies on POC is limited overall, it had been shown 
that POC is principally effective when combined with other modalities of anti-
neoplastic therapies. One long-term follow up study demonstrated that 39% 
(n = 33 eyes) of the enrolled eyes were saved when treated with POC in addition 
to other concurrent treatment modalities. The same report indicated that two 
eyes treated by POC as monotherapy were cured and remained disease free on 
follow up [82].
6. Conclusions
In the last two decades, significant new approaches have been employed in 
the treatment of retinoblastoma which is a curable disease when diagnosed early. 
Modalities to avoid enucleation and minimize the short and long term effects of 
exposure to systemic chemotherapy and radiation therapy continue to evolve and 
now set the platform in the treatment of retinoblastoma. Despite new techniques 
such as selective intra-arterial and intravitreal chemotherapy, it is paramount to 
individualize therapy according to multiple factors including patient age, tumor 
location, stage of disease, size, and extension, along with realistic visual expecta-
tions. Personalized medicine will be able to tailor therapy with the best response 
and safety in children with retinoblastoma.
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